Pfizer
New York, NY, USA
ROLE SUMMARY A world where people with cancer live better and longer lives, that’s Pfizer Oncology’s vision. We are accelerating breakthrough medicines that bring new hope to patients everywhere. Many of these breakthroughs are biologic buy-and-bill products like Elrexfio and Padcev, among others in our pipeline. By 2030, we anticipate biologics will account for 65% of the Pfizer Oncology business vs. today’s 6%. At a time of rapid market evolution, account consolidation, increasing account influence and a shift in the definition of value in the US oncology marketplace, business success in buy-and-bill biologics requires a deep understanding of provider dynamics and a careful balance of near-term actions with long-term impact. To address this, US Oncology has built a market-leading buy-and-bill capability to spearhead provider strategy for our growing portfolio of biologic medicines. The Director, Biologics Value Strategy is a key member of the...